All
Early-Phase Trial to Study Novel Drug, With or Without Keytruda, in Solid Cancers
September 27th 2022The novel drug PY159 will be studied as a single agent and in combination with Keytruda for patients with certain solid tumors — including ovarian, pancreatic, lung, head and neck, colorectal and breast cancers.
Phase 3 Trial to Study an Immunochemotherapy Regimen in Platinum-Resistant/Refractory Ovarian Cancer
September 26th 2022The OnPrime trial will investigate if adding Olvi-Vec, a modified virus, to chemotherapy and Avastin will improve outcomes for pretreated platinum-resistant or refractory ovarian cancer.
The power of a strong doctor-patient partnership and positivity when fighting lymphoma
September 26th 2022Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) cancer survivor Louise (left) and her oncologist, Dr. Ruemu Birhiray (right), built a lasting relationship as they navigated Louise’s diagnosis and relapse. This article is sponsored by MorphoSys and Incyte.
When Cancer Treatment Leads to a Secondary Cancer: Survivor Shares Her Story of Angiosarcoma
September 23rd 2022Seven years after completing breast cancer treatment, Angelia Carpenter was shocked to discover she had angiosarcoma, a rare cancer that may have been associated with her breast cancer treatment.
Blood Test Results May Offer Clues to Neurotoxicity Risk After CAR-T Cell Therapy in Cancer
September 22nd 2022Patients with blood cancer who have higher levels of neurofilament light chains — which indicate brain injury — were found to be more likely to develop neurotoxicity after CAR-T cell therapy, according to recent research.